

Article

Synthesis of Both Ionic Species of Ammonium Dithiocarbamate Derived Cholic Acid Moieties

Juha Koivukorpi and Erkki Kolehmainen *

Department of Chemistry, FI-40014 University of Jyväskylä, Finland

* Author to whom correspondence should be addressed; E-Mail: erkki.t.kolehmainen@jyu.fi; Tel.: +358-14260-2653.

Received: 1 July 2011; in revised form: 18 July 2011 / Accepted: 25 July 2011 /

Published: 26 July 2011

Abstract: The reaction of 3-aminopropylamide of cholic acid with CS₂ produced a bile acid derivative of dithiocarbamic acid which further formed an ammonium salt with another molecule of 3-aminopropylamide of cholic acid. The cationic 3-ammonium propylamide of cholic acid did not react further with CS₂ and the formed salt was stable in the reaction mixture, even when excess CS₂ was used. When the reaction was carried out in the presence of aqueous sodium hydroxide, only the bile acid derivative of sodium dithiocarbamate was formed. The dithiocarbamate derivatives were characterized by ¹H- and ¹³C-NMR spectroscopy and ESI-TOF mass spectrometry.

Keywords: cholic acid; dithiocarbamate; steroid; NMR spectroscopy; amine

1. Introduction

It is known that amines react with CS₂ forming dithiocarbamates [1–6]. Recently, Yavari *et al.* [7] have reported new synthetic strategies to prepare dithiocarbamates due to their large application potential. Dithiocarbamates exhibit numerous biological activities [9–12] and they are used in agriculture [12–14] and as linkers in solid-phase organic synthesis [15–17]. Further, dithiocarbamates are also widely used in medicinal chemistry and they have found application in cancer therapy [18,19]. As a biologically important expansion of the topic, we now present the synthesis and characterization of cholic acid-derived ammonium dithiocarbamates. This straightforward synthetic method offers an effective route to bile acid derivatives with increased water solubility, which is an essential property in


the design of physiologically active receptors [20,21] and drug carriers [22]. The synthetic route and numbering of **2** are shown in Scheme 1.

2. Results and Discussion

2.1. Chemistry

As the first step, *N*-(3-aminopropyl)-3- α ,7- α ,12- α -trihydroxy-5- β -cholan-24-amide (**1**) was prepared by a reaction of methyl cholate (methyl 3- α ,7- α ,12- α -trihydroxy-5- β -cholan-24-oate) with 1,3-diaminopropane (7 days at r.t.) [23]. Then compound **1** was allowed to react with CS₂ in methanol to form the desired product, *N*-(3-aminopropyl)-3- α ,7- α ,12- α -trihydroxy-5- β -cholan-24-oyl dithiocarbamate of *N*-(3-ammoniumpropyl)-3- α ,7- α ,12- α -trihydroxy-5- β -cholan-24-oic acid amide (**2**).

Scheme 1. Synthesis and numbering of **2**.



2.2. Spectroscopy

The structural characterization of **2** is based on one-dimensional ¹H-, ¹³C-, and ¹³C DEPT-135 data, as well as two-dimensional PFG DQF ¹H-¹H COSY [24-26], PFG ¹H-¹³C HMQC [27,28], PFG ¹H-¹³C HMBC [29] NMR studies and mass spectra, as well as elemental analysis. The ¹H- and ¹³C-NMR spectra of the sodium dithiocarbamate derivative of cholic acid 3-aminopropylamide was also used to distinguish the assignments of anionic and cationic parts. ¹H-NMR spectral assignments of non-steroidal parts and some of the steroidal part are presented in Figure 2, where the signals marked in blue coming from the cationic part and those marked in red from the anionic part, respectively. Their unambiguous assignments are based on the comparison of the ¹H-NMR spectra of **1** with the cholic acid-derived sodium dithiocarbamate prepared in the presence of aqueous sodium hydroxide and PFG DQF ¹H, ¹H COSY correlations. The signals originating from protons 3, 7, 12, Me-18, Me-19, Me-21 and 23 of the bile acid moieties in both ionic species overlap. For the assignment of the ¹³C-NMR spectrum (Figure 3 and Table 1) the reference data [30] and heteronuclear chemical shift correlation measurements PFG ¹H, ¹³C HMQC and HMBC were used. Unfortunately the ammonium

dithiocarbamate moiety of **2** was not thermally stable and it degraded in one week, whereas the sodium salt remained unchanged for several months when stored at room temperature.

Figure 2. ^1H -NMR spectrum of **2** in CD_3OD at 303 K and its partial assignment.




Figure 3. ^{13}C -NMR spectrum of **2** in CD_3OD at 303 K.




Table 1. ^{13}C NMR chemical shifts (± 0.1 ppm) of **2** from int. TMS in CD_3OD at 303 K.

Carbon	δ (ppm)	Carbon	δ (ppm)
1,1'	36.6	15,15'	24.4
2,2'	31.3	16,16'	28.8
3,3'	73.0	17,17'	48.2,48.1
4,4'	40.6	18,18'	13.2
5,5'	43.3	19,19'	23.4
6,6'	37.0	20,20'	37.2
7,7'	69.1	21,21'	18.0
8,8'	41.1	22,22'	33.5,33.4
9,9'	28.0	23,23'	34.5,34.2
10,10'	36.0	24,24'	176.8,177.6
11,11'	29.9	25,25'	37.8,37.2
12,12'	74.0	26,26'	29.9,29.1
13,13'	47.6	27,27'	45.9,38.6
14,14'	43.1	28	214.7

3. Experimental

3.1. General

All reagents and solvents of analytical grade were purchased from Sigma-Aldrich and were used without further purification. ^1H - and ^{13}C -NMR experiments were run on a Bruker Avance DRX 500 FT NMR spectrometer equipped with a 5 mm diameter inverse detection probehead and z-gradient accessory. ^1H chemical shifts were referenced to the center peak of the CD_2HOD quintet ($\delta(^1\text{H}) = 3.31$ ppm) and ^{13}C chemical shifts to the center peak of the CD_3OD heptet ($\delta(^{13}\text{C}) = 49.15$ ppm) from the internal TMS. Mass spectra were run with a QSTAR Elite MS/MS mass spectrometer system. Elemental analyses were performed on a Perkin Elmer 2400, series II, CHNS/O analyzer.

3.2. Synthesis of *N*-(3-aminopropyl)-3- α ,7- α ,12- α -trihydroxy-5- β -cholan-24-oyl dithiocarbamate of *N*-(3-ammoniumpropyl)-3- α ,7- α ,12- α -trihydroxy-5- β -cholan-24-oic acid amide (**2**)

3-Aminopropylamide of cholic acid (**1**) (100 mg, 0.22 mmol) and CS_2 (30 μL , 0.50 mmol) were dissolved in methanol (10 mL) and stirred overnight at room temperature. After that the solvent and an excess CS_2 was removed *in vacuo*. Yield 100%. ^1H -NMR (methanol- d_4): δ (ppm) = 0.71 (Me-18, 6H, s), 0.92 (Me-19, 6H, s), 1.06 (Me-21, 6H, d), 1.07-2.06 (44H), 2.08-2.20 (2H), 2.21-2.33 (6H), 3.01 (2H, t), 3.22 (2H, t), 3.31 (2H, t), 3.37 (2H, m), 3.63 (2H, t), 3.80 (2H, d), 3.95 (2H, s), 4.83 (12H). MS (ESI-TOF): $m/z = 1006$ $[\text{M}+\text{H}]^+$, 1028 $[\text{M}+\text{Na}]^+$, 465 $[\text{M}-\text{C}_{28}\text{H}_{47}\text{N}_2\text{O}_4\text{S}_2]^+$, 539 $[\text{M}-\text{C}_{27}\text{H}_{49}\text{N}_2\text{O}_4]^-$. M.W. ($\text{C}_{55}\text{H}_{96}\text{N}_4\text{O}_8\text{S}_2$) = 1005.50. Elemental analysis: calcd (%) for $\text{C}_{55}\text{H}_{96}\text{N}_4\text{O}_8\text{S}_2 \cdot 5 \text{H}_2\text{O}$: C, 60.30; H, 9.75; N, 5.11. Found C, 60.38; H, 9.42; N, 5.02.

4. Conclusions

We have demonstrated the straightforward synthesis of the cholic acid derived ammonium dithiocarbamate in both ionic species in 100% yield. We are planning to extend this approach starting

from other ω -aminoalkylamides of other bile acids. The sodium salts of their dithiocarbamates are very promising starting materials in the preparation of dithiocarbamate gold(III) complexes, which have been shown to possess cytotoxic properties. They are being evaluated as potential antitumor agents as an alternative to cisplatin [18,31-33].

Acknowledgements

We are grateful to special laboratory technician Reijo Kauppinen for his help in running the NMR spectra, to special laboratory technician Mirja Lahtiperä for mass spectral determinations and to laboratory technician Elina Hautakangas for elemental analysis. Emer. Matti Nurmi and Wendie Nurmi are thanked for the revision of the English language.

References

1. Critchfield, F.E.; Johnson, J.B. Reaction of carbon disulfide with primary and secondary aliphatic amines as analytical tool. *Anal. Chem.* **1956**, *28*, 430-436.
2. Sassaman, M.B.; Giovanelli, J.; Sood, V.K.; Eckelman, W.C. Synthesis and screening of conformationally restricted and conformationally free *N*-(tertiary aminoalkyl)dithiocarbamic acids and esters as inhibitors of neuronal nitric oxide synthase. *Bioorg. Med. Chem.* **1998**, *6*, 1759-1766.
3. Sztanke, K.; Pasternak, K.; Sidor-Wojtowicz, A.; Truchlińska, J.; Józwiak, K. Synthesis of imidazoline and imidazo[2,1-*c*][1,2,4]triazole aryl derivatives containing the methylthio group as possible antibacterial agents. *Bioorg. Med. Chem.* **2006**, *14*, 3635-3642.
4. Wong, R.; Dolman, S.J. Isothiocyanates from tosyl chloride mediated decomposition of in situ generated dithiocarbamic acid salts. *J. Org. Chem.* **2007**, *72*, 3969-3971.
5. Pérez, R.; Reyes, O.; Suarez, M.; Garay, H.E.; Cruz, L.J.; Rodríguez, H.; Molero-Vilchez, M.D.; Ochoa, C. Solid phase synthesis of 3-(5'-carboxypentyl)-5-substituted tetrahydro-2*H*-1,3,5-thiadiazin-2-thione derivatives, *Tetrahedron Lett.* **2000**, *41*, 613-616.
6. Azizi, N.; Ebrahimi, F.; Aakbari, E.; Aryanasab, F.; Saidi, M.R. Waste-free and environment-friendly uncatalyzed synthesis of dithiocarbamates under solvent-free conditions. *Synlett.* **2007**, 2797-2800.
7. Yavari, I.; Seyfi, S.; Hossaini, Z.; Sabbaghan, M.; Shirgahi-Talari, F. Efficient synthesis of 2-thioxo-1,3-thiazolanes from primary amines, CS₂, and ethyl bromopyruvate. *Monatsh. Chem.* **2008**, *139*, 1479-1482.
8. Caldas, E.D.; Hosana Conceição, M.; Miranda, M.C.C.; Souza, L.; Lima, J.F. Determination of dithiocarbamate fungicide residues in food by a spectrophotometric method using a vertical disulfide reaction system. *J. Agric. Food Chem.* **2001**, *49*, 4521-4525.
9. Erian, A.W.; Sherif, S.M. The chemistry of thiocyanic esters. *Tetrahedron* **1999**, *55*, 7957-8024.
10. Beji, M.; Sbihi, H.; Baklouti, A.; Cambon, A. Synthesis of *F*-alkyl *N*-sulfonyl carbamates and thiocarbamates. *J. Fluor. Chem.* **1999**, *99*, 17-24.

11. Goel, A.; Mazur, S.J.; Fattah, R.J.; Hartman, T.L.; Turpin, J.A.; Huang, M.; Rice, W.G.; Appella, E.; Inman, J.K. Benzamide-based thiolcarbamates: a new class of HIV-1 NCp7 inhibitors. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 767-770.
12. Mizuno, T.; Nishiguchi, I.; Okushi, T.; Hirashima, T. Facile synthesis of S-alkyl thiocarbamates through reaction of carbamoyl lithium with elemental sulfur. *Tetrahedron Lett.* **1991**, *32*, 6867-6868.
13. Rafin, C.; Veignie, E.; Sancholle, M.; Postal, D.; Len, C.; Villa, P.; Ronco, G. Synthesis and antifungal activity of novel bisdithiocarbamate derivatives of carbohydrates against *Fusarium oxysporum* f. sp. lini. *J. Agric. Food Chem.* **2000**, *48*, 5283-5287.
14. Len, C.; Postal, D.; Ronco, G.; Villa, P.; Goubert, C.; Jeufrault, E.; Mathon, B.; Simon, H. Synthesis of carbamic esters derivatives of itols: Antifungal activity against various crop diseases. *J. Agric. Food Chem.* **1997**, *45*, 3-6.
15. Morf, P.; Raimondi, F.; Nothofer, H.G.; Schnyder, B.; Yasuda, A.; Wessels, J.M.; Jung, T.A. Dithiocarbamates: Functional and versatile linkers for the formation of self-assembled monolayers. *Langmuir* **2006**, *22*, 658-663.
16. McClain, A.; Hsieh, Y.L. Synthesis of polystyrene-supported dithiocarbamates and their complexation with metal ions. *J. Appl. Polym. Sci.* **2004**, *92*, 218-225.
17. Dunn, A.D.; Rudorf, W.D. *Carbon Disulphide in Organic Chemistry*; Ellis Horwood: Chichester, UK, 1989; pp. 226-367.
18. Ronconi, L.; Marzano, C.; Zanello, P.; Corsini, M.; Miolo, G.; Macca, C.; Trevisan, A.; Fregona, D. Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties. *J. Med. Chem.* **2006**, *49*, 1648-1657.
19. Elgemeie, G.H.; Sayed, S.H. Synthesis and chemistry of dithioles. *Synthesis* **2001**, 1747-1771.
20. Kalenius, E.; Koivukorpi, J.; Kolehmainen, E.; Vainiotalo, P. Noncovalent saccharide recognition by tetrakis(bile acid)-porphyrin conjugate: selectivity, co-operation and stability. *Eur. J. Org. Chem.* **2010**, 1052-1058.
21. Kralová, J.; Koivukorpi, J.; Kejik, Z.; Poucková, P.; Sievänen, E.; Kolehmainen, E.; Král, V. Porphyrin–bile acid conjugates: from saccharide recognition in the solution to the selective cancer cell fluorescence detection. *Org. Biomol. Chem.* **2008**, *6*, 1548-1552.
22. Lee, S.; Lee, J.; Lee, D.Y.; Kim, S.K.; Lee, Y.; Byun, Y. A new drug carrier, Nalpha-deoxycholy-L-lysyl-methylester, for enhancing insulin absorption in the intestine. *Diabetologia* **2005**, *48*, 405-411.
23. Valkonen, A.; Lahtinen, M.; Virtanen, E.; Kaikkonen, S.; Kolehmainen, E. Bile acid amidoalcohols: Simple organogelators, *Biosens. Bioelect.* **2004**, *20*, 1233-1241.
24. Rance, M.; Sørensen, O.W.; Bodenhausen, G.; Wagner, G.; Ernst, R.R.; Wüthrich, K. Improved spectral resolution in COSY ¹H NMR spectra of proteins via double quantum filtering. *Biochem. Biophys. Res. Commun.* **1984**, *117*, 479-485.
26. Derome, A.; Williamson, M. Rapid-pulsing artefacts in double-quantum-filtered COSY. *J. Magn. Reson.* **1990**, *88*, 177-185.
27. Bax, A.; Griffey, R.H.; Hawkins, B.L. Correlation of proton and nitrogen-15 chemical shifts by multiple quantum NMR. *J. Magn. Reson.* **1983**, *55*, 301-315.

28. Bax, A.; Subramanian, S. Sensitivity-enhanced two-dimensional heteronuclear shift correlation NMR spectroscopy. *J. Magn. Reson.* **1986**, *67*, 565-570.
29. Bax, A.; Summers, M.F. ^1H and ^{13}C assignments from sensitivity enhanced detection of heteronuclear multiple-bond connectivity by two-dimensional multiple quantum NMR. *J. Am. Chem. Soc.* **1986**, *108*, 2093-2094.
30. Dias, J.R.; Gao, H.; Kolehmainen, E. ^{13}C nuclear magnetic resonance data of bile acid derivatives. *Spectrochim. Acta Part A* **2000**, *56*, 53-77.
31. Messori, L.; Marcon, G.; Orioli, P. Gold(III) compounds as new family of anticancer drugs. *Bioinorg. Chem. Appl.* **2003**, *1*, 177-187.
32. Milacic, V.; Chen, D.; Ronconi, L.; Landis-Piwowar, L.R.; Fregona, D.; Dou, Q.P. A Novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. *Cancer Res.* **2006**, *66*, 10478-10486.
33. Aldinucci, D.; Lorenzon, D.; Stefani, L.; Giovagnini, L.; Colombatti, A.; Fregona, D. Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells *in vitro*. *Anticancer Drugs* **2007**, *18*, 323-332.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).